New pill aims to calm ulcerative colitis flare-ups in korean patients

NCT ID NCT06964113

Ongoing Disease control Sponsor: Eisai Korea Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a daily medication called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (no active symptoms) by week 10 or 22. Participants take the pill once daily and are monitored for up to 58 weeks. This is an open-label study, meaning everyone knows they are getting the active drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Eisai Site #1

Seoul, South Korea
Eisai Site #10

Seoul, South Korea
Eisai Site #11

Gyeongnam, South Korea
Eisai Site #12

Seoul, South Korea
Eisai Site #13

Busan, South Korea
Eisai Site #14

Seoul, South Korea
Eisai Site #15

Busan, South Korea
Eisai Site #16

Gyeonggi-do, South Korea
Eisai Site #17

Seoul, South Korea
Eisai Site #18

Jungnam, South Korea
Eisai Site #19

Seoul, South Korea
Eisai Site #2

Daejeon, South Korea
Eisai Site #3

Seoul, South Korea
Eisai Site #4

Gyeonggi-do, South Korea
Eisai Site #5

Seoul, South Korea
Eisai Site #6

Daegu, South Korea
Eisai Site #7

Jungnam, South Korea
Eisai Site #8

Busan, South Korea
Eisai Site #9

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.